caa a22 4500 469078251 CHVBK 20180323132941.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF00173537 doi (NATIONALLICENCE)springer-10.1007/BF00173537 M1 muscarinic receptors mediate intracellular calcium release in NB-OK1 human neuroblastoma cells [Elektronische Daten] [H. Boddeke, M. Buttini, M. Lichtsteiner, A. Enz] Summary: Muscarine acetylcholine receptors were characterized in NB-OK1 cells using radioligand (3H-NMS) binding experiments and second messenger (calcium and phosphatidylinositol (PI) turnover) studies. In radioligand binding experiments the displacement curves of pirenzepine (KI = 1.3 × 10−8 M), AF-Dx 116 (KI = 8.2 × 10−7 M), methoctramine (KI = 8.4 × 10−8 M) and parafluorohexahydrosiladifenidol (pF-HHSiD) (K1 = 1.8 × 10−8 M) were monophasic and indicated the presence of M 1 muscarinic receptors. Schild analysis with the muscarinic antagonists pirenzepine, AF-Dx 116, methoctramine and pF-HHSiD yielded pA2 values of 8.40 +- 0.13, 6.48 =- 0.09, 7.61 +- 0.12 and 7.22 +- 0.08 in the calcium experiments and pA2 values of 8.13 +- 0.30 and 6.26 +- 0.26, 7.65 +- 0.16 and 7.46 +- 0.11, respectively, in the PI turnover experiments. These results indicate that both the carbachol-induced increase in intracellular calcium and the increase in PI turnover are mediated by M1 muscarinic receptors. In calcium free buffer, stimulation with carbachol induced similar responses to those seen under control conditions. From functional and radioligand binding experiments we conclude that the muscarinic receptor expressed in NB-OK1 cells is the M1 subtype. In addition, the M1 receptor-induced calcium response is related to PI turnover and is independent on extracellular calcium. Springer-Verlag, 1992 NB-OK1 cells nationallicence M1 receptors nationallicence Radioligand binding nationallicence Calcium release nationallicence PI turnover nationallicence Boddeke H. Sandoz Pharma Ltd, Preclinical Research, CH-4002, Basle, Switzerland aut Buttini M. Sandoz Pharma Ltd, Preclinical Research, CH-4002, Basle, Switzerland aut Lichtsteiner M. Biochemical Laboratory, Psychiatric University Clinic, CH-4025, Basle, Switzerland aut Enz A. Sandoz Pharma Ltd, Preclinical Research, CH-4002, Basle, Switzerland aut Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 346/3(1992-09-01), 255-261 0028-1298 346:3<255 1992 346 210 https://doi.org/10.1007/BF00173537 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00173537 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Boddeke H. Sandoz Pharma Ltd, Preclinical Research, CH-4002, Basle, Switzerland aut NATIONALLICENCE 700 1- Buttini M. Sandoz Pharma Ltd, Preclinical Research, CH-4002, Basle, Switzerland aut NATIONALLICENCE 700 1- Lichtsteiner M. Biochemical Laboratory, Psychiatric University Clinic, CH-4025, Basle, Switzerland aut NATIONALLICENCE 700 1- Enz A. Sandoz Pharma Ltd, Preclinical Research, CH-4002, Basle, Switzerland aut NATIONALLICENCE 773 0- Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 346/3(1992-09-01), 255-261 0028-1298 346:3<255 1992 346 210 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer